Michelle Fodor

Statistics

Publications

Citations

2.2K

H-Index

Active since

2016

Affiliations

Novartis (United States)(Current)

Harvard University

Dana-Farber Cancer Institute

Novartis (Switzerland)

Novartis (China)

Michelle Fodor is an author at Novartis (United States) specializing in allosteric regulation, protein tyrosine phosphatase inhibitors, and molecular oncology.

Publications per year

2016–2025

Publications

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

Ying-Nan P. Chen, Matthew J. LaMarche, Ho Man Chan et al. · Nature · 2016 · 929 citations

Life Sciences, Cell Biology, Oncology +16

Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor

Jorge Fortanet, Christine Hiu-Tung Chen, Ying-Nan P. Chen et al. · Journal of Medicinal Chemistry · 2016 · 291 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer

Matthew J. LaMarche, Michael Acker, Andreea Argintaru et al. · Journal of Medicinal Chemistry · 2020 · 222 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition

Jonathan R. LaRochelle, Michelle Fodor, Vidyasiri Vemulapalli et al. · Nature Communications · 2018 · 171 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Dual Allosteric Inhibition of SHP2 Phosphatase

Michelle Fodor, Edmund V. Price, Ping Wang et al. · ACS Chemical Biology · 2018 · 130 citations · Full text

Life Sciences, Biochemistry, Medicinal Chemistry +17

1–5 of 13